The Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial was a landmark study that assessed the effects of dapagliflozin, an SGLT2 inhibitor, in HFrEF patients with or without type 2 diabetes. The gene discussed is SLC5A2; the disease is hydrops fetalis.